The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea (low-dose atropine) to slow the progression of myopia in children. The drug, developed by pharmaceutical company Santen, becomes the first licensed treatment to slow childhood myopia. The approval follows authorisation by the European Commission and the launch in Germany earlier this year. Short-sightedness […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!